OBJECTIVES: To describe the diagnosis of local failure after prostate brachytherapy (BT) and treatment options when recurrence is present.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS AND MATERIALS: Review of literature for local recurrence after prostate BT and salvage therapy was performed. A total of 6 patients with prostate-specific antigen increase were identified as local failures by transperineal mapping biopsy (TPMB) and treated with targeted focused therapy using cryoablation.
RESULTS: Local recurrence after prostate BT occurs in 2-20% and is dose dependent. The biologic effective dose greater than 200 Gy2 is associated with a less than 2% recurrence rate. Confirmatory biopsy should include both the prostate and seminal vesicles, as prostate cancer can be found in 20% of the latter. The pathologist should be experienced in evaluating post-irradiation tissue because of the difficulty in distinguishing benign irradiated prostate from residual or recurrent tumor. Whole gland salvage, whether by prostatectomy or cryoablation, is associated with high complication rates. Focal therapy has fewer complications but accurate targeting remains a concern. Newer diagnostic and targeting modalities such as multiparametric MRI and TPMB offer improved opportunity to increase lesion identification and ablation. A TPMB approach, which incorporates new biopsy needle design and interactive targeting software, may offer the best avenue to true focused therapy.
CONCLUSION: Local recurrences after prostate BT are uncommon because of high delivered radiation dose. When present, improved lesion identification and targeting may be associated with better cancer control and lower morbidity.
Stone NN, Unger P, Crawford ED, Stock RG. Are you the author?
Department of Urology, The Icahn School of Medicine at Mount Sinai, New York, NY; Department of Radiation Oncology, The Icahn School of Medicine at Mount Sinai, New York, NY; Department of Pathology, North Shore Health System at Lenox Hill Hospital, New York, NY; Department of Surgery, Division on Urology, The Anschutz Cancer Center, University of Colorado Health Sciences Center, Aurora, CO.
Reference: Brachytherapy. 2014 Sep 16. pii: S1538-4721(14)00638-2.